Cerebras Systems, the AI chip designer that went public just weeks ago on the NASDAQ under the ticker CBRS, is having a rough morning despite a first quarterly report that beat Wall Street on both revenue and the size of its losses. Shares dropped sharply on concerns about margin compression rather than any miss on the top line.
At a Glance
- CBRS trading at 188.56 USD, off 17.12% on the day as of June 21, 2026
- Q1 revenue of 193.4 million USD beat analyst consensus by roughly 10 million USD
- Adjusted gross margin guidance for Q2 cut to 36 to 38 percent, down from 47 percent in Q1
- Morgan Stanley raised its price target to 273 USD from 250 USD, calling the selloff overdone
- Stock sits roughly 4 percent above its IPO price of 185 USD but nearly 40 percent below its first-day closing price
| Price | 188.56 USD |
|---|---|
| Day change | -38.81 (-17.12%) |
| 52-week range | 185.22 – 386.34 |
| Market cap | $49.79B |
| RSI (14) | 34.13 |
| Volume | 14,583,022 |
A Debut Quarter That Should Have Been a Win
Cerebras designs specialized chips built for AI workloads, competing in a market dominated by Nvidia. The company priced its IPO at 185 USD and began trading on the NASDAQ last month, generating immediate excitement around the AI hardware story. Its first quarterly report as a public company arrived after the bell Tuesday and, by the numbers, looked clean: revenue of 193.4 million USD for Q1, roughly 10 million above the analyst consensus compiled by Visible Alpha, paired with an adjusted loss of just 2.48 million USD, smaller than the street had modeled. A narrower loss and a revenue beat on the first report out of the gate is exactly what a newly listed growth company wants to deliver.
Investors sold anyway. The immediate trigger is margin guidance. Cerebras said it expects adjusted gross margins of 36 to 38 percent in the current quarter, a steep step down from the 47 percent it posted in Q1. That kind of sequential compression raises an obvious question: how durable is the underlying business model if margins erode this quickly once the company is operating in public view?
The stock had already been under pressure through its brief life as a public company. Wednesday's decline extends a slide that has left CBRS shares down close to 40 percent from where they ended their first trading day. The 52 week range of 185.22 to 386.34 illustrates just how violent the arc has been since listing: the stock nearly doubled from its IPO price before retreating almost all of those gains. At 188.56 USD, it is trading barely above the floor of that range.
The Morgan Stanley Counterargument
Not every analyst sees a crisis. Morgan Stanley pushed back on the selloff Wednesday morning, raising its price target on CBRS to 273 USD from 250 USD. The analysts told clients that demand for Cerebras chips remains strong and that "nothing in these numbers was disappointing." Their interpretation of the margin guidance is that the company may be intentionally cautious as it finds its footing in its first few quarters as a public company, sandbagging the outlook rather than telegraphing structural deterioration.
That reading is plausible, and Morgan Stanley is a credible voice. It is also worth noting, without editorializing, that investment banks maintaining bullish ratings on recent IPO clients are a familiar feature of post-listing coverage. Readers can weigh that dynamic for themselves. The price target of 273 USD would represent a roughly 45 percent premium to the current price, so the bull case is not timid.
What the Numbers Say
Cerebras carries a market cap of 49.79 billion USD at the current price. No P/E ratio is applicable given the company is not yet generating net income on a GAAP basis, and no dividend exists, making yield irrelevant at this stage. For early stage tech listings, those absences are normal, but they do mean the valuation rests entirely on revenue growth expectations and the long term margin story, both of which are now under scrutiny.
The RSI reading of 34.13 puts CBRS in oversold territory by the conventional threshold of 30. Momentum indicators do not predict reversals, but an RSI this low does signal that selling pressure has been sustained and aggressive. The 52 week high of 386.34 USD sits more than 100 percent above the current price, which reflects how dramatically sentiment has shifted since the early post-IPO enthusiasm faded.
On valuation, the 49.79 billion USD market cap against annualized Q1 revenue of roughly 774 million USD implies a price to sales multiple above 60 times. That is an extraordinarily rich multiple, even by AI sector standards, and it assumes the company can scale revenue substantially while simultaneously rebuilding margins. The Q2 gross margin guide of 36 to 38 percent complicates that assumption. If the business is accepting lower margins to win customers or fulfill large contracts, investors need clarity on whether that is a temporary dynamic or a sign that competitive pricing pressure is biting.
Bull Case vs. Bear Case
The bull case centers on demand. Morgan Stanley's read is that chip demand is strong, and Cerebras beat estimates on its first report. The AI infrastructure buildout remains one of the most capital intensive investment cycles in recent memory, and companies offering an alternative to Nvidia's dominant position have a credible addressable market. If margin compression is transitional, tied to early contract terms or one-off costs as the company scales production, the business could look quite different in four to six quarters.
The bear case is harder to dismiss. A drop from 47 percent gross margins to a guided 36 to 38 percent in a single quarter is not a rounding error. It is a 10 percentage point or more move in the wrong direction, and the company has not yet shown a sustained track record as a public entity. The stock's proximity to its IPO price of 185 USD, after briefly touching nearly 386 USD, tells a story about how quickly the narrative can reverse. At a market cap approaching 50 billion USD on annualized revenue below 800 million USD, there is limited room for execution stumbles.
Where Cerebras Goes From Here
The Q2 results, due later this summer, will be the real test. If margins stabilize or recover and revenue continues to outpace consensus, the Morgan Stanley thesis gets traction. If the gross margin compression deepens or revenue momentum stalls, the stock's thin cushion above its IPO price becomes a more relevant number to watch. Cerebras entered public markets with high expectations baked in. The first report showed it can beat on the top line. The harder proof, sustainable margins at scale, remains unfinished business.